The role of autologous stem cell transplantation in peripheral T cell lymphoma: a long-term follow-up single-center experience

  • Malte Roerden
  • Juliane S. WalzEmail author
  • Martin R. Müller
  • Martin Sökler
  • Birgit Federmann
  • Lothar Kanz
  • Wolfgang Bethge
  • Wichard Vogel
Original Article – Clinical Oncology



Peripheral T cell lymphomas (PTCL) are a rare and heterogeneous group of aggressive non-Hodgkin lymphomas, showing a generally poor prognosis. In this retrospective analysis, we aimed to investigate the impact of autologous stem cell transplantation (autoSCT) in PTCL.


A retrospective analysis of 58 consecutive unselected PTCL patients aged 21–71 years undergoing autoSCT as first-line consolidation as well as in the relapse setting was performed.


The median follow-up time was 67 months. A 5-year overall survival (OS) of 53% and a 5-year progression-free survival (PFS) after autoSCT of 44% was achieved. The overall relapse rate after autoSCT was 50%. On multivariate analysis, standard baseline characteristics such as age, disease stage and international prognostic index (IPI) score failed to predict outcome in our cohort. First-line treatment with autoSCT was not associated with a benefit in OS when compared to patients receiving autoSCT at relapse. Notably, autoSCT seemed to be a suitable approach even for older transplant-eligible patients (aged ≥ 60 years), with a similar 5-year OS of 49% when compared to younger patients.


Our study suggests that autoSCT can achieve long-term survival in PTCL patients even after relapse and should also be considered for eligible older patients.


PTCL T cell lymphoma Non-Hodgkin lymphoma Autologous stem cell transplantation AutoSCT 



No Funding was received for this study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

432_2019_2999_MOESM1_ESM.docx (16 kb)
Supplementary Table S1 Peripheral blood stem cell harvest. CHO(E)P cyclophosphamide, doxorubicin, vincristine, (etoposide), prednisone, VACOP-B etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin, DHAP dexamethasone, high-dose cytarabine, cisplatin, VIPE etoposide, ifosfamide, cisplatin, epirubicin, bw body weight (DOCX 16 kb)


  1. Advani S et al (1980) Immune dysfunction in non-Hodgkin’s lymphoma. Cancer 45:2843–2848CrossRefGoogle Scholar
  2. Brugger W, Bross K, Frisch J, Dern P, Weber B, Mertelsmann R, Kanz L (1992) Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin [see comments]. Blood 79:1193–1200Google Scholar
  3. Cederleuf H et al (2017) Outcome of peripheral T cell lymphoma in first complete remission: a Danish–Swedish population-based study. Leuk Lymphoma 58:2815–2823CrossRefGoogle Scholar
  4. Cheson BD et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17:1244CrossRefGoogle Scholar
  5. Chihara D et al (2017) The survival outcome of patients with relapsed/refractory peripheral T cell lymphoma-not otherwise specified and angioimmunoblastic T cell lymphoma. Br J Haematol 176:750–758. CrossRefGoogle Scholar
  6. Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon P, Diebold J (1990) Peripheral T cell lymphomas have a worse prognosis than B cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann Oncol 1:45–50CrossRefGoogle Scholar
  7. Corradini P et al (2004) Graft-versus-lymphoma effect in relapsed peripheral T cell non-Hodgkin’s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22:2172–2176CrossRefGoogle Scholar
  8. Corradini P et al (2006) Long-term follow-up of patients with peripheral T cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20:1533CrossRefGoogle Scholar
  9. d’Amore F et al (2006) Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T cell lymphomas (PTCL)-a phase II Study of the Nordic Lymphoma Group (NLG). Blood 108(11):401Google Scholar
  10. d’Amore F et al (2012) Up-front autologous stem-cell transplantation in peripheral T cell lymphoma: NLG-T-01. J Clin Oncol 30:3093–3099CrossRefGoogle Scholar
  11. d’Amore F et al (2015) Peripheral T cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:v108–v115CrossRefGoogle Scholar
  12. Dueck G et al (2010) Interim report of a phase 2 clinical trial of lenalidomide for T cell non-Hodgkin lymphoma. Cancer 116:4541–4548CrossRefGoogle Scholar
  13. Ellin F, Landstrom J, Jerkeman M, Relander T (2014) Real-world data on prognostic factors and treatment in peripheral T cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124:1570–1577. CrossRefGoogle Scholar
  14. Fanale MA et al (2014) Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T cell lymphomas: results of a phase I study. J Clin Oncol 32:3137CrossRefGoogle Scholar
  15. Foss FM, Zinzani PL, Vose JM, Gascoyne RD, Rosen ST, Tobinai K (2011) Peripheral T cell lymphoma. Blood 117:6756–6767. CrossRefGoogle Scholar
  16. Fossard G et al (2017) Role of up-front autologous stem-cell transplantation in peripheral T cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol 29:715–723CrossRefGoogle Scholar
  17. Gallamini A et al (2007) Alemtuzumab (campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316–2323CrossRefGoogle Scholar
  18. Gkotzamanidou M, Papadimitriou CA (2014) Peripheral T cell lymphoma: the role of hematopoietic stem cell transplantation. Crit Rev Oncol/Hematol 89:248–261CrossRefGoogle Scholar
  19. Gutiérrez-García G et al (2010) Comparison of four prognostic scores in peripheral T cell lymphoma. Ann Oncol 22:397–404CrossRefGoogle Scholar
  20. Haas R et al (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787–3794Google Scholar
  21. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA, Devine SM (2008) Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transplant 14:480–483CrossRefGoogle Scholar
  22. Horwitz SM et al (2014) Objective responses in relapsed T cell lymphomas with single agent brentuximab vedotin. Blood 123:3095–3100. CrossRefGoogle Scholar
  23. Jacquy C et al (2000) A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin’s lymphoma: one-half of patients significantly mobilize malignant cells. Br J Haematol 110:631–637CrossRefGoogle Scholar
  24. Kanakry JA et al (2013) Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 19:602–606. CrossRefGoogle Scholar
  25. Kharfan-Dabaja MA et al (2017) Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 23:1826–1838CrossRefGoogle Scholar
  26. Le Gouill S et al (2008) Graft-versus-lymphoma effect for aggressive T cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 26:2264–2271. CrossRefGoogle Scholar
  27. Mak V et al (2013) Survival of patients with peripheral T cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 31:1970–1976CrossRefGoogle Scholar
  28. Moskowitz AJ, Lunning M, Horwitz SM (2014) How I treat the peripheral T cell lymphomas. Blood 123:2636–2644. CrossRefGoogle Scholar
  29. Nickelsen M et al (2009) High-dose CHOP plus etoposide (MegaCHOEP) in T cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 20:1977–1984CrossRefGoogle Scholar
  30. Philip T et al (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545CrossRefGoogle Scholar
  31. Piccaluga PP, Agostinelli C, Gazzola A, Mannu C, Bacci F, Sabattini E, Pileri SA (2010) Prognostic markers in peripheral T cell lymphoma. Curr Hematol Malig Rep 5:222–228CrossRefGoogle Scholar
  32. Piekarz RL et al (2011) Phase 2 trial of romidepsin in patients with peripheral T cell lymphoma. Blood 117:5827–5834CrossRefGoogle Scholar
  33. Project IT-CL (2008) International peripheral T cell and natural killer/T cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130. CrossRefGoogle Scholar
  34. Reimer P et al (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T cell lymphomas: results of a prospective multicenter study. J Clin Oncol 27:106–113CrossRefGoogle Scholar
  35. Rodriguez J et al (2007) The results of consolidation with autologous stem-cell transplantation in patients with peripheral T cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 18:652–657CrossRefGoogle Scholar
  36. Rodríguez J et al (2007) Frontline autologous stem cell transplantation in high-risk peripheral T cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 79:32–38CrossRefGoogle Scholar
  37. Rohlfing S et al (2018) The impact of stem cell transplantation on the natural course of peripheral T cell lymphoma: a real-world experience. Ann Hematol 97:1241–1250. CrossRefGoogle Scholar
  38. Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Contemp Clin Trials 17:343–346CrossRefGoogle Scholar
  39. Smith SM et al (2013) Hematopoietic cell transplantation for systemic mature T cell non-Hodgkin lymphoma. J Clin Oncol 31:3100CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Hematology, Oncology, Clinical Immunology and RheumatologyUniversity Hospital TübingenTübingenGermany
  2. 2.Department of Pathology and NeuropathologyUniversity Hospital TübingenTübingenGermany

Personalised recommendations